Ng. Angiotensinconverting enzyme in serum was normal (42 U/l; normal range 15?0 U/l). Serum antibodies against the aquaporin-4 water channel, thyroid peroxidase, thyreoglobulin, glutamic acid decarboxylase, GQ1b and onconeural antibodies (anti-amphiphysin, anti-Ri, anti-Yo, anti-Hu, anti-CV2/CRMP5, anti-Ma2/Ta, antiNMDA, LGI-1, GAD) as well as anti-cardiolipin immunoglobulinwere all negative. A screen for antibodies against extractable nuclear and anti-nuclear antigens was negative. Three long-term blood pressure measurements were normal (,130/80 mmHg) with nocturnal dipping. Arylsulfatase A activity and serum very long-chain free fatty acid levels were within normal ranges. Analysis of Notch3 mutations, consistent with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), was negative. Cerebral MR- and catheter angiography was normal with no evidence for vasculitis. Although no angiokeratomas were found, a skin biopsy was done that showed a normal lipid content. However, intraepidermal nerve fiber (IENF) density was reduced (index patient: 18325633 6 IENF/mm; normal: .9 IENF/mm; Supporting Information S1), and along with the typical clinical presentation a small-fiber neuropathy was diagnosed. Transesophageal echocardiogram, renal ultrasound and urine analysis as well as ophthalmological and dermatological examination did not show other typical organ manifestations of FD. In conclusion, the diagnostic work-up provided no indication of inflammatory, neoplastic, metabolic, degenerative or congenital diseases. Of note, no classical risk factors of WML were present. Patients II.3, II.4, II.6, III.7, III.8, III.11 and III.14, all of which carried GLA D313Y, also underwent detailed clinical examinations (Table 2). Subjects II.3 and II.7 presented with unspecific “cardiac dysfunction”. Only patient II.3 had mild cardiovascular risk factors (well-treated arterial hypertension and well-treated hyperlipidemia). To exclude cerebral manifestations, brain MRI were performed in subjects II.3, II.4, II.6, II.7, III.8, III.11 and III.14. Although no Sense 59TGTGGGAATCCGACGAATG-39 and antisense 59- GTCATATGGTGGAGCTGTGGG-39 for N-Cadherin; sense 59CGGGAATGCAGTTGAGGATC-39 and FD-specific organ manifestations were found, all patients showed different Title Loaded From File extents (lesion volumes ranged from 8.1 ml to 42.9 ml; mean 23.4 ml 612.9 ml) of multifocal WML (Figure 3). Localisation of WML were primarily subcortical with punctuate lesions (patient II.6), but showed also confluent, periventricular involvement (patient II.3). MR images of patient II.3 showed a severe leukoencephalopathy with confluent cortical and subcortical lesions and large lesion load (42.9 ml). Overall, lesion loads were age-related, but WML were already present in young family members without any vascular risk factor (III.8 [49 y], III.11 [34 y], and III.14 [41 y]). Brain MRI was also performed in two family members that do not carry the GLA D313Y mutation. These controls (III.16 [25 y], III.17 [32 y]) showed no WMLs (Figure 4). Gadolinium enhancement was not seen in any of the cases.Genetic and Biochemical AnalysisRe-sequencing of all seven GLA exons and adjacent 59- and 39exon-intron-boundaries confirmed the exclusive presence of D313Y in exon 6 in all affected subjects (Figure 1, Table 2). GLA enzyme activities in leukocytes were in the normal range, or at the lower limit, but GLA activities in plasma were decreased (Table 2). Measurements of lyso-Gb3 content in blood plasma, as an additional marker for FD, were in the normal range (Table 2). To check whether GLA expression is a.Ng. Angiotensinconverting enzyme in serum was normal (42 U/l; normal range 15?0 U/l). Serum antibodies against the aquaporin-4 water channel, thyroid peroxidase, thyreoglobulin, glutamic acid decarboxylase, GQ1b and onconeural antibodies (anti-amphiphysin, anti-Ri, anti-Yo, anti-Hu, anti-CV2/CRMP5, anti-Ma2/Ta, antiNMDA, LGI-1, GAD) as well as anti-cardiolipin immunoglobulinwere all negative. A screen for antibodies against extractable nuclear and anti-nuclear antigens was negative. Three long-term blood pressure measurements were normal (,130/80 mmHg) with nocturnal dipping. Arylsulfatase A activity and serum very long-chain free fatty acid levels were within normal ranges. Analysis of Notch3 mutations, consistent with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), was negative. Cerebral MR- and catheter angiography was normal with no evidence for vasculitis. Although no angiokeratomas were found, a skin biopsy was done that showed a normal lipid content. However, intraepidermal nerve fiber (IENF) density was reduced (index patient: 18325633 6 IENF/mm; normal: .9 IENF/mm; Supporting Information S1), and along with the typical clinical presentation a small-fiber neuropathy was diagnosed. Transesophageal echocardiogram, renal ultrasound and urine analysis as well as ophthalmological and dermatological examination did not show other typical organ manifestations of FD. In conclusion, the diagnostic work-up provided no indication of inflammatory, neoplastic, metabolic, degenerative or congenital diseases. Of note, no classical risk factors of WML were present. Patients II.3, II.4, II.6, III.7, III.8, III.11 and III.14, all of which carried GLA D313Y, also underwent detailed clinical examinations (Table 2). Subjects II.3 and II.7 presented with unspecific “cardiac dysfunction”. Only patient II.3 had mild cardiovascular risk factors (well-treated arterial hypertension and well-treated hyperlipidemia). To exclude cerebral manifestations, brain MRI were performed in subjects II.3, II.4, II.6, II.7, III.8, III.11 and III.14. Although no FD-specific organ manifestations were found, all patients showed different extents (lesion volumes ranged from 8.1 ml to 42.9 ml; mean 23.4 ml 612.9 ml) of multifocal WML (Figure 3). Localisation of WML were primarily subcortical with punctuate lesions (patient II.6), but showed also confluent, periventricular involvement (patient II.3). MR images of patient II.3 showed a severe leukoencephalopathy with confluent cortical and subcortical lesions and large lesion load (42.9 ml). Overall, lesion loads were age-related, but WML were already present in young family members without any vascular risk factor (III.8 [49 y], III.11 [34 y], and III.14 [41 y]). Brain MRI was also performed in two family members that do not carry the GLA D313Y mutation. These controls (III.16 [25 y], III.17 [32 y]) showed no WMLs (Figure 4). Gadolinium enhancement was not seen in any of the cases.Genetic and Biochemical AnalysisRe-sequencing of all seven GLA exons and adjacent 59- and 39exon-intron-boundaries confirmed the exclusive presence of D313Y in exon 6 in all affected subjects (Figure 1, Table 2). GLA enzyme activities in leukocytes were in the normal range, or at the lower limit, but GLA activities in plasma were decreased (Table 2). Measurements of lyso-Gb3 content in blood plasma, as an additional marker for FD, were in the normal range (Table 2). To check whether GLA expression is a.